{"database": "lobbying", "table": "lobbying_activities", "rows": [[1919531, "7eb7825a-b4b9-43d0-909f-1b1cdfcc1e42", "Q4", "TEVA PHARMACEUTICALS USA, INC.", 76695, "TEVA PHARMACEUTICALS USA INC", 2016, "fourth_quarter", "PHA", "Prescription drug abuse; drug labeling and electronic labeling proposals; counterfeit drug proposals; FY 2017 Appropriations for Agriculture, Rural Development, Food & Drug Administration and Related Agencies; FY 2017 Labor, HHS & Related Agencies Appropriations; \"21st Century Cures\" review/initiative; HR 9, Innovation Act; HR 1353 PATIENT Act; Section 505(b)(2) new drug applications and exclusivity period; drug pricing proposals and issues; and biosimilars reimbursement.", "Food & Drug Administration (FDA),HOUSE OF REPRESENTATIVES,SENATE,U.S. Trade Representative (USTR)", null, 930000, 0, 0, "2017-01-18T17:29:55-05:00"]], "columns": ["id", "filing_uuid", "filing_type", "registrant_name", "registrant_id", "client_name", "filing_year", "filing_period", "issue_code", "specific_issues", "government_entities", "income_amount", "expense_amount", "is_no_activity", "is_termination", "received_date"], "primary_keys": ["id"], "primary_key_values": ["1919531"], "units": {}, "query_ms": 14.02543403673917, "source": "Federal Register API & Regulations.gov API", "source_url": "https://www.federalregister.gov/developers/api/v1", "license": "Public Domain (U.S. Government data)", "license_url": "https://www.regulations.gov/faq"}